State-court mass tort cases present challenges to the safeguards against forum-shopping, and a recent decision in the Reglan/metoclopramide litigation is a prime example.
In July, the Pennsylvania Superior Court voted, 2-1, in Hassett v. Dafoe and three companion cases not to apply pre-emption at the motion-to-dismiss stage to failure-to-warn claims involving generic versions of Reglan, a gastric pharmaceutical. Although this decision is pending further review, the ruling, if left to stand, will be an outlier, denying dismissal despite two recent U.S. Supreme Court cases (and the great weight of additional authority) holding that materially identical cases against generic drug manufacturers are pre-empted by federal law.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
